Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: New Nordic Studies, Vaccine Solidarity Pledges, And The Re-Start Of COPCOV

Executive Summary

As the US snaps up most supplies of remdesivir, the EU says it is committed to ensuring global access to coronavirus medicines and international donors have been asked to pledge more money to pay for vaccines, medicines and tests. The past week has also seen some ups and downs for trials of various products for the treatment or prevention of COVID-19. 

You may also be interested in...



Renewed Political Pressure on Hydroxychloroquine for COVID Highlights Need For Independent US FDA

Bowing to President Trump’s latest push to authorize the anti-malarial drug for COVID-19 could damage the reputation of the agency for the duration of the pandemic and beyond, experts say, arguing it may be the best example yet of why the FDA’s decision making needs to be more clearly delineated from the country’s political leadership.

WHO Launches Global Push For Tools To Tackle COVID-19

A global collaboration initiative launched by the World Health Organization is intended to foster the development of COVID-19 vaccines, medicines and diagnostics and to make sure they reach all those who need them. 

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS142478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel